Cargando…
Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension
This study assessed the efficacy and safety of sacubitril/valsartan in 23 hemodialysis patients with hypertension (mean age 70 years; male 69.6%) after switching from azilsartan, an angiotensin receptor blocker. Both at baseline and 3 months after the start of sacubitril/valsartan treatment, home bl...
Autores principales: | Iwashima, Yoshio, Fukushima, Hiromichi, Horio, Takeshi, Rai, Tatemitsu, Ishimitsu, Toshihiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994168/ https://www.ncbi.nlm.nih.gov/pubmed/36722379 http://dx.doi.org/10.1111/jch.14635 |
Ejemplares similares
-
The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients
por: Zhao, Cong, et al.
Publicado: (2022) -
Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients
por: Wang, Bin, et al.
Publicado: (2022) -
Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018) -
Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020) -
Renin profiling predicts neurohormonal response to sacubitril/valsartan
por: Vergaro, Giuseppe, et al.
Publicado: (2020)